EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Establishment of Translational Luciferase-Based Cancer Models to Evaluate Antitumoral Therapies

Martin R Ramos-Gonzalez iD, Nagabhishek Sirpu Natesh, Satyanarayana Rachagani, James Amos-Landgraf iD, Haval Shirwan iD, Esma S Yolcu iD, Jorge G Gomez-Gutierrez iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms251910418 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Martin R Ramos-Gonzalez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Roy Blunt NextGen Precision Health Institute, University of Missouri, Columbia, MO 65211, USA. Hauptthemen laut MEDLINE: Luciferases, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Missouri, Research Council Grant, University of Missouri EFCC Pilot Program, NIBIB NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Luciferase (luc) bioluminescence (BL) is the most used light-emitting protein that has been engineered to be expressed in multiple cancer cell lines, allowing for the detection of tumor nodules in vivo as it can penetrate most tissues. The goal of this study was to develop an oncolytic adenovirus (OAd)-resistant human triple-negative breast cancer (TNBC) that could express luciferase. Thus, when combining an OAd with chemotherapies or targeted therapies, we would be able to monitor the ability of these compounds to enhance OAd antitumor efficacy using BL in real time. The TNBC cell line HCC1937 was stably transfected with the plasmid pGL4.50[luc2/CMV/Hygro] (HCC1937/luc2). Once established, HCC1937/luc2 was orthotopically implanted in the 4th mammary gland fat pad of NSG (non-obese diabetic severe combined immunodeficiency disease gamma) female mice. Bioluminescence imaging (BLI) revealed that the HCC1937/luc2 cell line developed orthotopic breast tumor and lung metastasis over time. However, the integration of luc plasmid modified the HCC1937 phenotype, making HCC1937/luc2 more sensitive to OAdmCherry compared to the parental cell line and blunting the interferon (IFN) antiviral response. Testing two additional luc cell lines revealed that this was not a universal response; however, proper controls would need to be evaluated, as the integration of luciferase could affect the cells’ response to different treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LuciferasesTriple Negative Breast NeoplasmsAnimalsHumansFemaleMiceCell Line, TumorXenograft Model Antitumor AssaysAdenoviridaeOncolytic VirotherapyLuminescent MeasurementsMice, SCIDMice, Inbred NODOncolytic Viruses

Stichwörter der Autor:innen

bioluminescenceluciferasemetastasesoncolytic adenovirusorthotopictumor

Substanzen

Luciferases

Autor:innen und Institutionen

  • Roy Blunt NextGen Precision Health Institute, University of Missouri, Columbia, MO 65211, USA.
  • Ellis Fischel Cancer Center, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
  • Department of Veterinary Medicine and Surgery, University of Missouri, Columbia, MO 65211, USA.
  • Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65211, USA.
  • Department of Pediatrics, School of Medicine, University of Missouri, Columbia, MO 65211, USA.

ORCID-Profile: Martin R Ramos-Gonzalez, James Amos-Landgraf, Haval Shirwan, Esma S Yolcu, Jorge G Gomez-Gutierrez

Förderung

  • University of Missouri, Research Council Grant
  • University of Missouri EFCC Pilot Program
  • NIBIB NIH HHS
  • Office of the Assistant Secretary of Defense for Health Affairs through the (Peer Reviewed Cancer Research Program, Idea Award)
  • NIBIB
  • niversity of Missouri EFCC Pilot Program and Research Council

Zitieren

APA

Ramos-Gonzalez, M. R., Sirpu Natesh, N., Rachagani, S., Amos-Landgraf, J., Shirwan, H., Yolcu, E. S., & Gomez-Gutierrez, J. G. (2024). Establishment of Translational Luciferase-Based Cancer Models to Evaluate Antitumoral Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910418

Vancouver

Ramos-Gonzalez MR, Sirpu Natesh N, Rachagani S, Amos-Landgraf J, Shirwan H, Yolcu ES, et al. Establishment of Translational Luciferase-Based Cancer Models to Evaluate Antitumoral Therapies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910418

BibTeX
@article{RamosGonzalez2024,
  author = {Ramos-Gonzalez, Martin R and Sirpu Natesh, Nagabhishek and Rachagani, Satyanarayana and Amos-Landgraf, James and Shirwan, Haval and Yolcu, Esma S and Gomez-Gutierrez, Jorge G},
  title = {Establishment of Translational Luciferase-Based Cancer Models to Evaluate Antitumoral Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms251910418}
}
Kostenlos starten →